comparison of valproate and oxcarbazepine for epilepsy in children

Comparison of efficacy of Sodium Valproate and Oxacarbazepine monotherapy in children with benign childhood occipital epilepsy less than 18 years of age: a single blind randomized controlled noninferiority trial - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082840

Enrollment

100

Registered

2025-03-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset

Interventions

Intervention1: valproate: valproate orally 20 mg/kg/day daily in two divided doses for six months Control Intervention1: oxcarbazepine: oxcarbazepine orally 15 mg/kg/day daily in two divided doses

Eligibility

Inclusion criteria

Inclusion criteria: Children with confirmed diagnosis of occipital epilepsy

Exclusion criteria

Exclusion criteria: Children with known allergy to valproate or oxcarbazepine

Design outcomes

Primary

Measure	Time frame
Number of children without any recurrence of seizure in both armsTimepoint: Number of children without any recurrence of seizure in both arms	—

Secondary

Measure	Time frame
Number of children with normal EEG in both groups at six monthsTimepoint: At six months after enrollment in study	—

Countries

India

Contacts

Public ContactPRATEEK KUMAR PANDA

AIIMS, RISHIKESH

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026